Jackson Creek Investment Advisors LLC Sells 397 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Jackson Creek Investment Advisors LLC lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 3.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,770 shares of the biotechnology company’s stock after selling 397 shares during the period. Jackson Creek Investment Advisors LLC’s holdings in Blueprint Medicines were worth $1,114,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Quarry LP bought a new stake in Blueprint Medicines in the third quarter valued at approximately $32,000. R Squared Ltd bought a new stake in shares of Blueprint Medicines in the 4th quarter valued at $51,000. Covestor Ltd increased its position in shares of Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after buying an additional 403 shares during the period. Asset Management One Co. Ltd. bought a new position in Blueprint Medicines during the fourth quarter worth $88,000. Finally, Van ECK Associates Corp lifted its holdings in Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 363 shares during the period.

Insiders Place Their Bets

In related news, CEO Kate Haviland sold 1,446 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now directly owns 149,378 shares of the company’s stock, valued at approximately $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ariel Hurley sold 1,819 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total value of $169,639.94. Following the completion of the transaction, the insider now directly owns 14,967 shares in the company, valued at approximately $1,395,822.42. This represents a 10.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,427 shares of company stock valued at $4,837,801 in the last 90 days. 4.21% of the stock is currently owned by corporate insiders.

Blueprint Medicines Trading Down 1.6 %

NASDAQ BPMC opened at $87.12 on Friday. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The business has a fifty day simple moving average of $99.43 and a 200 day simple moving average of $94.27. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90. The firm has a market capitalization of $5.57 billion, a P/E ratio of -80.67 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Piper Sandler lifted their target price on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Wedbush reissued an “outperform” rating and issued a $128.00 price target on shares of Blueprint Medicines in a research note on Friday, February 28th. StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. Finally, JMP Securities reiterated a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Blueprint Medicines presently has an average rating of “Moderate Buy” and an average target price of $125.21.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.